AstraZeneca Pharma India announced Financial Results Q1 2024

The comprehensive analytics outlining the performance and outlook of AstraZeneca Pharma India Limited‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at AstraZeneca Pharma India Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 31.16 %. However, it did see a marginal increase of 1.13 % from the previous quarter. Expenses ticked up slightly by 4.72 % quarter-on-quarter, aligning with the annual rise of 53.11 %. Operating profit, while down -43.37 % compared to last year, faced a quarter-on-quarter dip of -23.1 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -12.93 %, but a shrinkage of -3.09 % sequentially. Other income fell by -668.07 % compared to the last quarter, despite an annual decline of -707.33 %. Interest expenses surged remarkably by 57.14 % from the previous quarter, yet the year-over-year decrease remains at a moderate -26.67 %. Depreciation costs climbed by 3.99 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 2.89 %. Profit before tax declined annually by -121.24 % but saw a reduction from the preceding quarter by -127.89 %.
Tax expenses as a percentage of profits decreased slightly by -46.78 % compared to last year, with a more notable quarter-on-quarter decrease of -49.59 %. Net profit fell by -121.89 % year-on-year but witnessed a -129.86 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -121.91 % but a quarterly fall of -129.89 %. In summary, AstraZeneca Pharma India Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing AstraZeneca Pharma India Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 31.16 % year-on-year growth, however, there was a minor increase of 1.13 % from the previous quarter. Expenses rose by 53.11 % compared to the previous year, with a 4.72 % increase quarter-on-quarter. Operating Profit dropped by -43.37 % annually, and saw a -23.1 % decrease from the last quarter.
Net Profit showed yearly decrease of -121.89 %, and experienced a -129.86 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -121.91 % annually, however dipped by -129.89 % compared to the last quarter. In essence, while AstraZeneca Pharma India Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.